<DOC>
	<DOCNO>NCT00550199</DOCNO>
	<brief_summary>This single center phase I dose escalation trial . LBH589 administer orally twice weekly . Gemcitabine administer intravenously 30 minute day 1 , 8 , 15 every 28 day . Dose escalation begin Dose Level 1 . Three patient enrol dose level . If 1/3 patient experience dose-limiting toxicity , dose level expand 6 patient . If 2/6 patient experience dose-limiting toxicity specific dose level , previous dose level consider recommended phase II dose . Dose escalation continue maximum tolerate dose determine dose level outline protocol complete . A total 10 patient treat dose recommended phase II evaluation ass safety combination regimen . Toxicity assessment ongoing disease assessment repeat every 2 treatment cycle . Patients allow continue study disease progression unless toxicity warrant drug discontinuation .</brief_summary>
	<brief_title>LBH589 Gemcitabine Treatment Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Histologically document metastatic locally advanced , incurable malignancy gemcitabine clinically appropriate ( e.g. , nonsmall cell lung cancer , breast , ovarian , bladder cancer lymphoma ) . 2 . Male female patient age ≥ 18 year old . 3 . Maximum 3 prior regimen metastatic setting allow may include targeted agent , immunotherapy chemotherapy . 4 . Measurable disease RECIST criterion . 5 . ECOG PS 0 1 . 6 . Laboratory value follow : ANC &gt; 1500/μL Hgb &gt; 9 g/dL Platelets &gt; 100,000/uL Bilirubin &lt; 1.5 mg/dL AST/SGOT ALT/SGPT &lt; 2.5 x ULN &lt; 5.0 x ULN patient liver metastasis Creatinine &lt; 2.0 mg/dL Or 24hour Creatinine Clearance &gt; 50 ml/min Albumin &gt; 3 g/dL Potassium &gt; low limit normal ( LLN ) Phosphorous &gt; LLN Calcium &gt; LLN Magnesium &gt; LLN 8 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . 9 . Life expectancy &gt; 12 week . 10 . Accessible treatment followup . 11 . All patient must able understand nature study give write informed consent prior study entry . 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer . Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment 2 . Impaired cardiac function include follow : Screening ECG QTc &gt; 450 msec . Congenital long QT syndrome . History sustain ventricular tachycardia . Any history ventricular fibrillation torsades de pointes . Bradycardia define heart rate &lt; 50 beat per minute . Patients wit pacemaker heart rate &gt; 50 beat per minute eligible . Myocardial infarction unstable angina within 6 month study entry . Congestive heart failure ( NY Heart Association class III IV . Right bundle branch block leave anterior hemiblock ( bifasicular block ) . Atrial fibrillation flutter . 3 . Uncontrolled hypertension ( systolic blood pressure [ BP ] 180 diastolic BP &gt; 100mm Hg ) uncontrolled cardiac arrhythmia . 4 . Active CNS disease , include meningeal metastasis . 5 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 6 . Unresolved diarrhea &gt; CTCAE grade 1 . 7 . Chemotherapy , investigational drug therapy , major surgery &lt; 4 week prior start study drug patient recover side effect previous therapy . 8 . Patient &lt; 5 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 9 . Concomitant use anticancer therapy radiation therapy protocol require gemcitabine . 10 . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 7 day first administration oral LBH589 . 11 . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom . 12 . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . 13 . Other concurrent severe , uncontrolled infection intercurrent illness , include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 14 . Patients uncontrolled coagulopathy . 15 . Abnormal thyroid function ( TSH free T4 ) detect screen . Patients known hypothyroidism stable thyroid replacement eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase I</keyword>
	<keyword>LBH589</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>